PHAT News and Press, Phathom Pharmaceuticals Inc. From 12/14/23

Amendment provides more favorable terms including a 14-month extension of the interest-only period and maturity date until December 2027 Up to an additional $100 million in non- dilutive capital available subject to the achievement of certain revenue milestones Cash runway...

2023-12-06 08:44:34 ET More on Phathom Pharmaceuticals Following Up On Phathom Pharmaceuticals Phathom Pharmaceuticals gets FDA approval for Erosive GERD drug Phathom wins FDA nod for reformulated antibiotic Seeking Alpha’s Quant Rating on Phathom Phar...

New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD, the largest subcategory of GERD July 19, 2024 PDUFA target action date assigned by the FDA FLORHAM PARK, ...

VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA tablets in 30-count bottles are now commercially available for the healing and ...

Phathom Pharmaceuticals Inc. (PHAT) is expected to report $-0.95 for Q3 2023

2023-11-09 17:15:33 ET More on Phathom Pharmaceuticals Following Up On Phathom Pharmaceuticals Phathom Pharmaceuticals gets FDA approval for Erosive GERD drug Phathom wins FDA nod for reformulated antibiotic For further details see: Phantom Pharmaceutical...

2023-11-09 09:07:48 ET More on Phathom Pharmaceuticals Following Up On Phathom Pharmaceuticals Phathom Pharmaceuticals gets FDA approval for Erosive GERD drug Phathom wins FDA nod for reformulated antibiotic Seeking Alpha’s Quant Rating on Phathom Phar...

VOQUEZNA® (vonoprazan) tablets approved by the U.S. Food and Drug Administration (FDA) for the treatment of Erosive GERD and relief of associated heartburn in adults, marking the first major innovation in the U.S. Erosive GERD market in over 30 years Commercial availability of VOQUEZNA f...

2023-11-01 17:45:03 ET More on Phathom Pharmaceuticals Following Up On Phathom Pharmaceuticals Phathom wins FDA nod for reformulated antibiotic Phathom files for FDA approval of vonoprazan for Non-Erosive GERD Seeking Alpha’s Quant Rating on Phathom Ph...

FDA approval marks the first major innovation to the U.S. Erosive GERD market in over 30 years VOQUEZNA ® met the primary endpoints and key secondary superiority endpoints in the pivotal Phase 3 PHALCON-EE trial evaluating VOQUEZNA in comparison to a standard-of-care proton pump in...